Products - Metabolic conditions | Topic | NICE

Showing 5 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elamipretide for treating Barth syndrome in people of any age [ID6545]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC